Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Semaglutide-Induced Weight Loss Does Not Impair Muscle Function and Improves Endurance Running Capacity in Obese Mice.

BACKGROUND

Semaglutide, a member of the glucagon-like peptide-1 receptor agonists, induces substantial weight loss, primarily through appetite suppression and reduced energy intake. In addition to fat mass reduction, a considerable loss of lean body mass is also observed. How these effects...

🗓️ 2026-11-17
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSemaglutide-Induced Weight Loss Does Not Impair Muscle Function and Improves Endurance Running Capacity in Obese Mice.

A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy.

BACKGROUND

Hypertrophic cardiomyopathy (HCM) involves left ventricular hypertrophy and metabolic dysfunction. Given the role of skeletal muscle in systemic metabolism, we investigated whether activin type II receptor inhibition with CDD866, a murinized bimagrumab analogue that induces skeletal muscle hypertrophy, improves physical...

🗓️ 2026-11-11
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreA Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy.

ZIF-8-Based Nanodelivery of Tectorigenin for Alleviating Skeletal Muscle Atrophy via Inhibition of Oxidative Stress and Inflammation.

BACKGROUND

Skeletal muscle atrophy is a pathological condition characterized by a progressive loss of muscle mass and function. Its core mechanisms involve an imbalance between protein synthesis and degradation, caused by oxidative stress and inflammation. Tectorigenin (TG) shows therapeutic potential but...

🗓️ 2026-11-10
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreZIF-8-Based Nanodelivery of Tectorigenin for Alleviating Skeletal Muscle Atrophy via Inhibition of Oxidative Stress and Inflammation.

Metabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy.

BACKGROUND

Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is one of the most common adult-onset myopathies and is causally associated with a contraction of the D4Z4 macrosatellite repeat array on chromosome 4. It presents with a variable pattern of progressive muscle weakness...

🗓️ 2026-11-08
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMetabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy.

Atovaquone impedes muscle wasting in pancreatic cancer by AMPK modulation.

Cancer-induced cachexia is a multifactorial syndrome characterized by systemic inflammation and progressive skeletal muscle and fat wasting. More than 80% pancreatic cancer patients exhibit a cachectic phenotype, which significantly contributes to the overall mortality of cancer patients. Till now, there...

🗓️ 2026-11-08
📰 Publication: Cancer Letters
Read MoreAtovaquone impedes muscle wasting in pancreatic cancer by AMPK modulation.

Sexually Dimorphic Response to Dietary Restriction-Induced Longevity and Muscle Preservation in Nothobranchius furzeri.

Age-related skeletal muscle decline (sarcopenia) contributes to frailty and mortality, yet how sex influences muscle aging and dietary interventions remains unclear. Using the short-lived vertebrate Nothobranchius furzeri, we investigated how sex and intermittent fasting (IF) interact to regulate lifespan and...

🗓️ 2026-11-06
📰 Publication: Aging Cell
Read MoreSexually Dimorphic Response to Dietary Restriction-Induced Longevity and Muscle Preservation in Nothobranchius furzeri.

Mitochondrial Transplantation Preserves Regenerative Capacity of Denervated Skeletal Muscle by Disrupting a Ca 2+ Overload-Mitophagy-Ferroptosis Circuit.

BACKGROUND

Denervation-induced muscle atrophy progresses during the interval between nerve injury and reinnervation, and depletion of muscle satellite cells (MuSCs) contributes to impaired functional recovery. Although mitochondrial dysfunction and impaired quality control are implicated in muscle wasting, whether excessive mitochondrial turnover...

🗓️ 2026-11-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMitochondrial Transplantation Preserves Regenerative Capacity of Denervated Skeletal Muscle by Disrupting a Ca 2+ Overload-Mitophagy-Ferroptosis Circuit.

S100A9 Mediates Neuroblastoma-Associated Skeletal Muscle Atrophy via O-GlcNAcylation Repression and Activate Mitophagy Activation.

BACKGROUND

In patients with neuroblastoma (NB), skeletal muscle atrophy is a key factor linked to poor survival and decreased long-term quality of life. Nevertheless, there are still insufficient therapeutic methods that work, and the underlying mechanisms remain unclear. As persistent inflammation...

🗓️ 2026-11-05
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreS100A9 Mediates Neuroblastoma-Associated Skeletal Muscle Atrophy via O-GlcNAcylation Repression and Activate Mitophagy Activation.

Remodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy.

BACKGROUND

The global prevalence of iron deficiency anaemia (IDA) is about 25% and even higher in women of reproductive age and children. IDA can impair skeletal muscle by disrupting oxygen utilization, energy production and contractile function. Haematological effects of intravenous (IV)...

🗓️ 2026-11-04
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRemodelling of Skeletal Muscle During Iron Deficiency Anaemia and Recovery After Intravenous Iron Therapy.

Aquaporin-4 Orchestrates Muscle Cell Differentiation and Satellite Cell Preservation: A Novel Target in Age-Related Muscle Decline.

BACKGROUND

Impaired muscle regeneration is a key contributor to age-related muscle decline, yet the molecular mechanisms linking muscle water homeostasis to regenerative failure remain incompletely understood. Aquaporin-4 (AQP4), a major skeletal muscle water channel, may have functions beyond water transport that...

🗓️ 2026-10-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAquaporin-4 Orchestrates Muscle Cell Differentiation and Satellite Cell Preservation: A Novel Target in Age-Related Muscle Decline.

Frailty Rather Than Sonographic Muscle Measurement Predicts Outcome in Liver Cirrhosis.

BACKGROUND

Sarcopenia and frailty are frequent in patients with liver cirrhosis and are associated with morbidity and mortality. Given the limitations of computed tomography (CT) for routine assessment of muscle loss and the need for practical bedside assessment, we aimed to...

🗓️ 2026-10-27
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreFrailty Rather Than Sonographic Muscle Measurement Predicts Outcome in Liver Cirrhosis.

Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes.

BACKGROUND

Urolithin A (UA) and urolithin B (UB) are gut microbiota-derived metabolites of ellagitannins reported to influence mitochondrial function, inflammation and muscle metabolism. Their comparative transcriptomic effects in human skeletal muscle cells remain undefined. We characterized UA- and UB-induced molecular responses...

🗓️ 2026-09-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreExploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes.

Pancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.

BACKGROUND

Cancer cachexia, a debilitating syndrome characterized by muscle wasting, significantly impacts survival in gastrointestinal cancers like pancreatic cancer. Emerging evidence suggests a link between cancer cachexia and disrupted circadian rhythms in peripheral tissues, including locomotor muscles. However, circadian dysregulation in...

🗓️ 2026-09-23
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePancreatic Cancer Disrupts Circadian Patterns of Gene Expression in Cardiorespiratory Muscles.

Aging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.

Skeletal muscle aging is a major cause of frailty, metabolic dysfunction, and loss of independence in later life, yet it cannot be explained by muscle mass loss alone. Recent single-cell, multi-omics, and translational studies show that aged muscle is shaped...

🗓️ 2026-09-22
Read MoreAging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 – Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 – The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4: 89–94.

Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr 2008; 27: 793–799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014; 5: 1–3.

Argiles JM, Busquets S, Stemmler B, López-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Current Opinion in Pharmacology 2015; 22: 100–106.

Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2015; 6: 197–207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!